Role of expression of prostaglandin synthases 1 and 2 and leukotriene C4 synthase in aspirin-intolerant asthma: a theoretical study.

Abstract:

:Altered expressions of the key enzymes in arachidonic acid (AA) metabolism, prostaglandin synthase 1 and 2 and cysteinyl leukotriene C(4) synthase, are of importance in understanding aspirin-induced asthma. We propose a mathematical model of AA metabolism and its interaction with non-steroidal anti-inflammatory drugs (NSAIDs). Model simulations depict the impact of modified expressions of the above enzymes on the time dependent synthesis of cysteinyl leukotrienes and anti-inflammatory prostaglandins before and during NSAID exposure in different model states describing healthy humans as well as aspirin-tolerant and -intolerant asthmatics. The results are compared and evaluated with experimental data taken from the literature. Our results identify the decreased expression of prostaglandin H synthase 1 and increased expression of leukotriene C(4) synthase as the key elements in AA metabolism that contribute to increased leukotriene C(4) and decreased anti-inflammatory prostaglandins after NSAID dosing in aspirin-intolerant patients. On the other hand, the decreased expression of prostaglandin H synthase 2 implies permanently increased leukotriene C(4) and lowers the sensitivity to increased drug doses. The model is used for identification of susceptible patient populations for aspirin and ibuprofen, and for identification of critical aspirin doses that might induce bronchoconstriction.

authors

Dobovišek A,Fajmut A,Brumen M

doi

10.1007/s10928-011-9192-6

subject

Has Abstract

pub_date

2011-04-01 00:00:00

pages

261-78

issue

2

eissn

1567-567X

issn

1573-8744

journal_volume

38

pub_type

杂志文章
  • Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.

    abstract:AIM:Chemotherapy with indisulam causes myelosuppression. This study aimed to evaluate the influence of patient-related covariates on pharmacokinetics and pharmacodynamics, to identify patients at risk for severe myelosuppression and to develop a dosing algorithm for treatment optimization. METHODS:Pharmacokinetic and ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-009-9111-2

    authors: Zandvliet AS,Schellens JH,Copalu W,Beijnen JH,Huitema AD

    更新日期:2009-02-01 00:00:00

  • Reversible jump Markov chain Monte Carlo for deconvolution.

    abstract::To solve the problem of estimating an unknown input function to a linear time invariant system we propose an adaptive non-parametric method based on reversible jump Markov chain Monte Carlo (RJMCMC). We use piecewise polynomial functions (splines) to represent the input function. The RJMCMC algorithm allows the explor...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-006-9045-x

    authors: Kang D,Verotta D

    更新日期:2007-06-01 00:00:00

  • The design and analysis of parallel experiments to produce structurally identifiable models.

    abstract::Pharmacokinetic analysis in humans using compartmental models is restricted with respect to the estimation of parameter values. This is because the experimenter usually is only able to apply inputs and observations in a very small number of compartments in the system. This has implications for the structural identifia...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-012-9291-z

    authors: Cheung SY,Yates JW,Aarons L

    更新日期:2013-02-01 00:00:00

  • Analysis of PK/PD risk factors for development of type 2 diabetes in high risk population using Bayesian analysis of glucose-insulin kinetics.

    abstract::This study was designed to investigate the pharmacokinetics/pharmacodynamics (PK/PD) risk factors preceding the onset of type 2 diabetes using a population-based Bayesian nonlinear hierarchical model to describe the glucose-insulin kinetics. One hundred fifty-two healthy subjects with a family history of type 2 diabet...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-009-9130-z

    authors: Lin CW,Veng-Pedersen P

    更新日期:2009-10-01 00:00:00

  • Bioequivalence for highly variable drugs: regulatory agreements, disagreements, and harmonization.

    abstract::Regulatory authorities introduced procedures in the last decade for evaluating the bioequivalence (BE) for highly variable drugs. These approaches are similar in principle but differ in details. For example, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) recommend differing regulatory c...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,评审

    doi:10.1007/s10928-019-09623-w

    authors: Endrenyi L,Tothfalusi L

    更新日期:2019-04-01 00:00:00

  • Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.

    abstract::Tocilizumab is a recombinant humanized antihuman interleukin-6 receptor monoclonal antibody, which inhibits binding of IL-6 to its soluble (sIL-6R) and membrane-expressed (mIL-6R) receptors. The work investigated whether the observed decline in peripheral neutrophil and platelet counts after tocilizumab administration...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10928-011-9227-z

    authors: Gibiansky L,Frey N

    更新日期:2012-02-01 00:00:00

  • Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components.

    abstract::The volume of distribution at steady state (Vss) of therapeutic proteins is usually assessed by non-compartmental or compartmental pharmacokinetic (PK) analysis wherein errors may arise due to the elimination of therapeutic proteins from peripheral tissues that are not in rapid equilibrium with the sampling compartmen...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-011-9209-1

    authors: Richter WF,Grimm HP,Theil FP

    更新日期:2011-10-01 00:00:00

  • Modeling cancer-immune responses to therapy.

    abstract::Cancer therapies that harness the actions of the immune response, such as targeted monoclonal antibody treatments and therapeutic vaccines, are relatively new and promising in the landscape of cancer treatment options. Mathematical modeling and simulation of immune-modifying therapies can help to offset the costs of d...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-014-9386-9

    authors: dePillis LG,Eladdadi A,Radunskaya AE

    更新日期:2014-10-01 00:00:00

  • A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.

    abstract::HER2-positive breast cancer (BC) is a rapidly growing and aggressive BC subtype that predominantly affects younger women. Despite improvements in patient outcomes with anti-HER2 therapy, primary and/or acquired resistance remain a major clinical challenge. Here, we sought to use a quantitative systems pharmacological ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-020-09732-x

    authors: Franco YL,Ramakrishnan V,Vaidya TR,Mody H,Perez L,Ait-Oudhia S

    更新日期:2021-01-03 00:00:00

  • A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects.

    abstract::HbA1c is the most commonly used biomarker for the adequacy of glycemic management in diabetic patients and a surrogate endpoint for anti-diabetic drug approval. In spite of an empirical description for the relationship between average glucose (AG) and HbA1c concentrations, obtained from the A1c-derived average glucose...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-012-9289-6

    authors: Lledó-García R,Mazer NA,Karlsson MO

    更新日期:2013-04-01 00:00:00

  • Estimation of parameters for the elimination of an orally administered test substance with unknown absorption.

    abstract::Assessment of the elimination of an oral test dose based on plasma concentration values requires correction for the effect of gastric release and absorption. Irregular uptake processes should be described 'model independently', which requires estimation of a large number of absorption parameters. To limit the associat...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-013-9299-z

    authors: Vogt JA,Denzer C

    更新日期:2013-04-01 00:00:00

  • A Bayesian population analysis of the development of type 2 diabetes in the offspring of diabetic parents.

    abstract::Disease progression of type 2 diabetes (T2D) has received considerable attention, but little is known about the disease development of T2D. The purposes of this study were to identify disease development variables (DDV) for development of T2D and to compare corresponding models for disease development. All subjects in...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-011-9208-2

    authors: Lin CW,Warram JH,Veng-Pedersen P

    更新日期:2011-10-01 00:00:00

  • Lack of ethnic differences of moxifloxacin and metabolite pharmacokinetics in East Asian men.

    abstract::This study was designed to investigate ethnic differences in the pharmacokinetics (PKs) of moxifloxacin and its metabolites, M1 (sulfo conjugate) and M2 (acyl-glucuronate), among Japanese, Chinese, and Korean populations, following oral administration. We used a population PK modeling approach using data from a clinic...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-017-9556-7

    authors: Kaneko M,Aoyama T,Ishida Y,Miyamoto A,Saito Y,Tohkin M,Kawai S,Matsumoto Y

    更新日期:2018-04-01 00:00:00

  • A stochastic model describes the heterogeneous pharmacokinetics of cyclosporin.

    abstract::The pharmacokinetics of cyclosporin (CsA) are unusual because of several heterogeneous features which include the presence of more than one conformer, considerable accumulation in erythrocytes and lipoproteins, extensive plasma protein binding, distribution into deep tissues, biliary secretion and hepatic clearance in...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1012295014352

    authors: Claret L,Iliadis A,Macheras P

    更新日期:2001-10-01 00:00:00

  • Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation.

    abstract::Literature data are often reported as multiple (longitudinal) mean outcomes observed in several groups of patients within a study. Observations within a study are correlated because the patients come from a common population, and the mean observations over time within a treatment arm are correlated because they are ba...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-010-9152-6

    authors: Ahn JE,French JL

    更新日期:2010-04-01 00:00:00

  • The effect of using a robust optimality criterion in model based adaptive optimization.

    abstract::Optimizing designs using robust (global) optimality criteria has been shown to be a more flexible approach compared to using local optimality criteria. Additionally, model based adaptive optimal design (MBAOD) may be less sensitive to misspecification in the prior information available at the design stage. In this wor...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-017-9521-5

    authors: Strömberg EA,Hooker AC

    更新日期:2017-08-01 00:00:00

  • Challenges of a mechanistic feedback model describing nicotinic acid-induced changes in non-esterified fatty acids in rats.

    abstract::Previously, we developed a feedback model to describe the tolerance and oscillatory rebound of non-esterified fatty acid (NEFA) plasma concentrations in male Sprague Dawley rats after intravenous infusions of nicotinic acid (NiAc). This study challenges that model, using the following regimens of intravenous and oral ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-013-9325-1

    authors: Ahlström C,Peletier LA,Gabrielsson J

    更新日期:2013-08-01 00:00:00

  • Mathematical description of drug-target interactions: application to biologics that bind to targets with two binding sites.

    abstract::The emerging discipline of mathematical pharmacology occupies the space between advanced pharmacometrics and systems biology. A characteristic feature of the approach is application of advance mathematical methods to study the behavior of biological systems as described by mathematical (most often differential) equati...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-017-9546-9

    authors: Gibiansky L,Gibiansky E

    更新日期:2018-02-01 00:00:00

  • A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.

    abstract::Guselkumab, a human IgG1 monoclonal antibody that blocks interleukin-23, has been evaluated in one Phase 2 and two Phase 3 trials in patients with moderate-to-severe psoriasis, in which disease severity was assessed using Psoriasis Area and Severity Index (PASI) and Investigator's Global Assessment (IGA) scores. Throu...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9581-1

    authors: Hu C,Yao Z,Chen Y,Randazzo B,Zhang L,Xu Z,Sharma A,Zhou H

    更新日期:2018-08-01 00:00:00

  • Bioequivalence testing by statistical shape analysis.

    abstract::Bioequivalence testing has been traditionally centered in summary variables such as AUC, C (max) and t (max) which filter out the intrinsic information conveyed by discrete sequential concentration-time observations. Comparing entire concentration-time profiles between test and reference formulations for bioequivalenc...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-007-9055-3

    authors: Pereira LM

    更新日期:2007-08-01 00:00:00

  • General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

    abstract::Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characteriz...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1014414520282

    authors: Mager DE,Jusko WJ

    更新日期:2001-12-01 00:00:00

  • Assessing the dynamics of nuclear glucocorticoid-receptor complex: adding flexibility to gene expression modeling.

    abstract::A retrospective analysis was performed to modify our fourth-generation pharmacodynamic model for glucocorticoid receptor (GR) dynamics with incorporation of more physiological features. This modified model was developed by integrating previously reported free cytosolic GR and GR mRNA data following single (10, 50 mg/k...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-007-9049-1

    authors: Hazra A,DuBois DC,Almon RR,Jusko WJ

    更新日期:2007-06-01 00:00:00

  • Age-structured population model of cell survival.

    abstract::Age-structured cell population model was introduced to describe cell survival. The impact of the environment on the cell population is represented by drug plasma concentration. A key model variable is the hazard of cell removal that is a subject to the environment effect. The model is capable of describing cohort and ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-017-9520-6

    authors: Krzyzanski W,Wiczling P,Gebre A

    更新日期:2017-08-01 00:00:00

  • Modeling T cell responses to antigenic challenge.

    abstract::T cell responses are a crucial part of the adaptive immune system in the fight against infections. This article discusses the use of mathematical models for understanding the dynamics of cytotoxic T lymphocyte (CTL) responses against viral infections. Complementing experimental research, mathematical models have been ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,评审

    doi:10.1007/s10928-014-9387-8

    authors: Wodarz D

    更新日期:2014-10-01 00:00:00

  • Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients.

    abstract::A population pharmacokinetic analysis was conducted to characterize the pharmacokinetics of fexofenadine in Japanese pediatric patients (6 months through 16 years) with perennial allergic rhinitis or atopic dermatitis. The dataset was composed of 515 patients (including 109 adults), for a total of 1,080 concentration-...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10928-014-9356-2

    authors: Martinez JM,Khier S,Morita S,Rauch C,Fabre D

    更新日期:2014-04-01 00:00:00

  • A method of obtaining starting values of k(in) and k(out) for the indirect response models.

    abstract::A method based on the multivariate technique known as principal component analysis is proposed to obtain starting values for the rate constants of indirect response models. The method is not iterative and only requires standard deviation calculations for two quantities, which are simple functions of the measured pharm...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/b:jopa.0000029487.21238.5c

    authors: Mukherjee D,Hutmacher MM

    更新日期:2004-02-01 00:00:00

  • Benchmarking renin suppression and blood pressure reduction of direct renin inhibitor imarikiren through quantitative systems pharmacology modeling.

    abstract::Multiple classes of antihypertensive drugs inhibit components of the renin-angiotensin-aldosterone system (RAAS). The primary physiological effector of the RAAS is angiotensin II (AngII) bound to the AT1 receptor (AT1-bound AngII). There is a strong non-linear feedback from AT1-bound AngII on renin secretion. Since AT...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9612-y

    authors: Gebremichael Y,Lahu G,Vakilynejad M,Hallow KM

    更新日期:2019-02-01 00:00:00

  • A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

    abstract::Effective long-term treatment of Type 2 Diabetes Mellitus (T2DM) implies modification of the disease processes that cause this progressive disorder. This paper proposes a mechanism-based approach to disease progression modeling of T2DM that aims to provide the ability to describe and quantify the effects of treatment ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-006-9008-2

    authors: de Winter W,DeJongh J,Post T,Ploeger B,Urquhart R,Moules I,Eckland D,Danhof M

    更新日期:2006-06-01 00:00:00

  • Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations.

    abstract::The utilisation of physiologically-based pharmacokinetic models for the analysis of population data is an approach with progressively increasing impact. However, as we move from empirical to complex mechanistic model structures, incorporation of stochastic variability in model parameters can be challenging due to the ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-015-9418-0

    authors: Tsamandouras N,Wendling T,Rostami-Hodjegan A,Galetin A,Aarons L

    更新日期:2015-08-01 00:00:00

  • A reduction in between subject variability is not mandatory for selecting a new covariate.

    abstract::Population pharmacokinetic-pharmacodynamic analysis involves nonlinear hierarchical modelling where the mean response in a population and the variability in response from different sources are studied. It generally consists of two model hierarchies: a model for residual error and a model for heterogeneity termed betwe...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-012-9256-2

    authors: Lagishetty CV,Vajjah P,Duffull SB

    更新日期:2012-08-01 00:00:00